TY - JOUR
T1 - Global disparities in SARS-CoV-2 genomic surveillance
AU - Brito, Anderson F.
AU - Semenova, Elizaveta
AU - Dudas, Gytis
AU - Hassler, Gabriel W.
AU - Kalinich, Chaney C.
AU - Kraemer, Moritz U.G.
AU - Ho, Joses
AU - Tegally, Houriiyah
AU - Githinji, George
AU - Agoti, Charles N.
AU - Matkin, Lucy E.
AU - Whittaker, Charles
AU - Howden, Benjamin P.
AU - Sintchenko, Vitali
AU - Zuckerman, Neta S.
AU - Mor, Orna
AU - Blankenship, Heather M.
AU - de Oliveira, Tulio
AU - Lin, Raymond T.P.
AU - Siqueira, Marilda Mendonça
AU - Resende, Paola Cristina
AU - Vasconcelos, Ana Tereza R.
AU - Spilki, Fernando R.
AU - Aguiar, Renato Santana
AU - Alexiev, Ivailo
AU - Ivanov, Ivan N.
AU - Philipova, Ivva
AU - Carrington, Christine V.F.
AU - Sahadeo, Nikita S.D.
AU - Branda, Ben
AU - Gurry, Céline
AU - Maurer-Stroh, Sebastian
AU - Naidoo, Dhamari
AU - von Eije, Karin J.
AU - Perkins, Mark D.
AU - van Kerkhove, Maria
AU - Hill, Sarah C.
AU - Sabino, Ester C.
AU - Pybus, Oliver G.
AU - Dye, Christopher
AU - Bhatt, Samir
AU - Flaxman, Seth
AU - Suchard, Marc A.
AU - Grubaugh, Nathan D.
AU - Baele, Guy
AU - Faria, Nuno R.
AU - Communicable Diseases Genomics Network (Australia and New Zealand)
AU - COVID-19 Impact Project
AU - Danish Covid-19 Genome Consortium
AU - Fiocruz COVID-19 Genomic Surveillance Network
AU - GISAID core curation team
AU - Network for Genomic Surveillance in South Africa (NGS-SA)
AU - Swiss SARS-CoV-2 Sequencing Consortium
AU - Bulgarian SARS-CoV-2 sequencing group
N1 - Publisher Copyright:
© 2022. The Author(s).
PY - 2022
Y1 - 2022
N2 - Genomic sequencing is essential to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments, vaccines, and guide public health responses. To investigate the global SARS-CoV-2 genomic surveillance, we used sequences shared via GISAID to estimate the impact of sequencing intensity and turnaround times on variant detection in 189 countries. In the first two years of the pandemic, 78% of high-income countries sequenced >0.5% of their COVID-19 cases, while 42% of low- and middle-income countries reached that mark. Around 25% of the genomes from high income countries were submitted within 21 days, a pattern observed in 5% of the genomes from low- and middle-income countries. We found that sequencing around 0.5% of the cases, with a turnaround time <21 days, could provide a benchmark for SARS-CoV-2 genomic surveillance. Socioeconomic inequalities undermine the global pandemic preparedness, and efforts must be made to support low- and middle-income countries improve their local sequencing capacity.
AB - Genomic sequencing is essential to track the evolution and spread of SARS-CoV-2, optimize molecular tests, treatments, vaccines, and guide public health responses. To investigate the global SARS-CoV-2 genomic surveillance, we used sequences shared via GISAID to estimate the impact of sequencing intensity and turnaround times on variant detection in 189 countries. In the first two years of the pandemic, 78% of high-income countries sequenced >0.5% of their COVID-19 cases, while 42% of low- and middle-income countries reached that mark. Around 25% of the genomes from high income countries were submitted within 21 days, a pattern observed in 5% of the genomes from low- and middle-income countries. We found that sequencing around 0.5% of the cases, with a turnaround time <21 days, could provide a benchmark for SARS-CoV-2 genomic surveillance. Socioeconomic inequalities undermine the global pandemic preparedness, and efforts must be made to support low- and middle-income countries improve their local sequencing capacity.
U2 - 10.1038/s41467-022-33713-y
DO - 10.1038/s41467-022-33713-y
M3 - Journal article
C2 - 36385137
AN - SCOPUS:85142128821
SN - 2041-1723
VL - 13
SP - 7003
JO - Nature Communications
JF - Nature Communications
ER -